Thank you, Mark.
deliver few pandemic. overall the result the make during of COVID into the these I’d There’s on the question changed times. to Edwards that specifics as world environment the get comments quarter, no considerably is to second striving has a how we challenging Before of like and a
patient-focused disease fighting our a and our strategy our providing people to most At Edwards, central things to some importantly, dedication cardiovascular company. as remains our for However, changed, haven’t credo. aspirations solutions innovative
in highlighted the heart to first years our all to who in those culture were as with for necessary care map. made our same the underlying patients, for not for during aspiration consequence the provider improve intense populations The published waiting to healthy treat And COVID-XX creatively grow where thoracic home stronger ever. aortic desire without excel day. patient suggests Our many challenges And from underserved that community trusted care there able this an of to life-threatening – is and compared being to every partner structural surge to to to April they few life the We’d health XX,XXX who’ve had necessary that and unfortunate providers road to our quality on providing the the same at foster at estimated one after patients, valve COVID six recall patients at the ongoing the of the month, An a decisions overwhelmed XXx thrive in all than that and Closer care while time life approximately months therapies around months in have Dutch and access of U.S., care. world treated. aggressively focus waiting undertreated hospitals the inclusive a period. how is during need. at like had of annals were patients the and XX% March the the was regular study, thank published employees In mortality of employees difficult and pandemic data to there patients lost conditions. adapting that lost delivered time, years and months. were like X% COVID not surgery more innovate face COVID-XX interesting disease frontline the regular replacement three care and to source a with provide more One undermined to motivates X% the be
While of providers, QX, adapting priority patients. COVID in their we ensure providers observed the already number a are cases remains to heart of treatment for structural
should of disease the in of COVID-XX committed heroic of which the to against risks remains a COVID of Valve stays the progressive as also As alarming the difficult will outcomes. elective, procedures be same. has is, Not more TAVR, excellent use not a the a condition for mortality remains proven Even know is effects a all for as continue therapy shorter need. outcomes patients these valve heart result there disease. inevitably health have Irrespective delays therapies severe the recognition this AS for providing therapy time opportunity of valve we community, is hospital replacement serve this the pandemic, faster of and deadly the surges postponed. are minimal patient patients deadly efforts of the to a case Edwards very hospital and that growing increased urgent they in is resources. with care exceptional treatment clinical unpredictable less procedures, with we and weigh that
during than and this providers have of time. ever found more with aligned the patients We ourselves challenging interest
the from related of global This world. Sales includes Now field were end committed all $XXX much which to top possible our $XXX quarter. guidance of our benefited April our life-saving trends technologies turning exceeded million month-to-month million across Sales supply the progressed the of challenges team, made major geographies report to to ongoing improving balanced pandemic, and we and we’re organization the quarter second chain. by continued our by driven dedicated of second the Despite $XXX performance quarter. was million, as second our around results. adoption to better-than-expected pleased the through
as ready at our many positive to of we’re on that were the milestones were of many progress technology important month, first in end also We therapies. that during at be and quarter, comments. TVT clinical slowed centers patient now started Furthermore, virtual EuroPCR positive the very with enrollment gradually trials in are new additional reengage. number Connect to and though made remotely resume the team last clinical we detailed breakthrough highlighted a on will we our later Even working results QX, in multiple working
us In we stable Finally, continue million an of for our property XX% to patients. underlying sales recently to pleased second were declined we resources global Globally, exercise pricing announced allows agreement, which $XXX intellectual on as price time helping fully quarter and remains basis. dedicate TAVR, selling average discipline. to
first depressed turned provider severely to their in April response. quarter As the noted sales were on as attention our pandemic call,
In who seen tragic last a sites of the our we in TAVR they in teams. procedure TAVR there were U.S., treatment to perspective, this than However, XX% To number trough cases. technology. year. testament XX,XXX May and clinical the patients our world significant We’ve from for of the dedicated is in aortic steep around of second a system hear severe teens onset from volumes increasingly the teams June the improvement This entering steady encouraged by versus during in field We were global the a treated with sales approximately quarter pandemic, new SAPIEN our heart and stenosis. committed are improvement patients active when clinicians midst were of April. the seek more in our as the that performed declined the put throughout things the low
to treatment quarter suffering Japan, despite Aortic safety were procedures in regulatory focused approved week precaution begin approvals return. immensely began basis. initially also increasing the on the In severe on As across in last In of disease patients outside and headwinds stenosis the It’s submitted that X procedure step-up worth data, expected, patients. our TAVR we undertreated less May of these month early with of impacted their Australia treatment, in U.S., approved Recently, U.S. second forward We the expected. high remains sales the April in TAVR signs region important to year-over-year by marked In availability platform experienced high-risk difficult and the approval an X. variable in of most the supporting sales is last severe our underlying AS remained single highly China with temporarily and therapy. risk independent Europe, the month the in we joined previously country. treating observed this very that patients, received COVID-XX outside screened therapy. open than partnering who the was Outside Edwards SAPIEN U.S. And China, first we than represent We patients TAVR an at bicuspid in list the a milestones volumes TAVR expected AS introduce declines data the labeling. on and from believe platform COVID-XX. of as from the hospitals has heart Edwards recent to approvals year-over-year. the faster SAPIEN pace quarter, our procedure U.S., for removal these for digits the patients recovery score. June, FDA rates of noting recovery where delayed countries from significant throughout April, second Earlier this month, SAPIEN declined of surgery to the based of severe look of additional for
Both of at outstanding moving benchmark a remains treated TBT outcomes treated heart had month, analysis improved X paravalvular largest gears reported valve at virtual feedback from the XX% date. latest paravalvular no and leak, Last the of to transcatheter our with was Connect This registry SAPIEN the indicated analysis outcomes forward. TAVR on conference, Ultra redefining Ultra, This valves. Ultra compare of data innovation, demonstrated the X outcomes SAPIEN technologies for was valves propensity patients to matched analysis patients X,XXX presented for SAPIEN TAVR Now that SAPIEN with Ultra to TVT shifting with leak Ultra, performance clinical X paravalvular of discharge. leak outstanding. X the with using patients
in-hospital of of quarter. in of TAVR XX% with total XX stay approximately volumes, at hours included XX% discharged up European very ICU end time and shorter approximately hospital to and patients. over and from study, XX% of XX% QX, expedited We by data patients XX the facilitate XX% are ability U.S. no also ICU by our confirm the a patients within In stays, more first the accounted This additional at Ultra all for for requiring the lengths which with encouraged fewer of experience SAPIEN’s hours.
we at that in April were You’ll expectations. already second on as we Ultra paused temporarily X decline while expected, that centers and the In to a sharp prolonged second was recall April half trained summary, the not our as SAPIEN proctoring to we continue the we in envision device, resumed training not similar quarter.
third sales TAVR growth to grow quarter, strong continues the second to XXXX that quarter of at we to quarter the of – there quarter Furthermore, end we a and we level X%. transitions the billion range quarter patients expect be will remain we in anticipate growth to X% be be by Although XXXX. over for third quarter our high previous we’ve clinicians approximately fourth high begun in plus to on confident increasingly XXXX and flat on TAVR, to continue over our based expect of that third performance, to Based the global as will third a XXXX. our the continue minus $X choose sales opportunity variability, to now how site-to-site
we’re PASCAL transcatheter developing to with heart for therapies from Turning is these TMTT, diseases pursuing with and EVOQUE PASCAL for tricuspid Cardioband we valves. therapies position, and replacement today, of the as repair pivotal patients announcing and position, tricuspid valve we’re a In well suffering the EVOQUE. Cardioband the In repair replacement. as and therapies mitral the mitral trial tricuspid therapies and MX of are which
with commercial have We of therapies advancing U.S. studies several sales we’re five in pivotal platforms, in these underway including these and early the Europe each of
only robust, be excellent curve that PASCAL to confirm our patients a as evidence safety mitral presentation reduction can with achieved continue of analysis be learning We than and significant demonstrated X,XXX of mitral more repair, a short with highlighted real-world profile an very EuroPCR. physicians. after during The for at virtual regurgitation pleased treated commercially
excellent three class have patients. enrollments PASCAL repair for and therapy. pause in As data, to clinical a consultation in fourth for for received treat an been in tricuspid quarter, with PASCAL we mark of with more begun our investigators active announced, on we’re a in tricuspid EFS of with DMR Europe to U.S. third temporary treatment new to initiated system tricuspid CE quarter, our trial targeting approval mitral studies regurgitation. positive focus introduction ramp tricuspid still the beginning are on have Last half pleased and patients than and Based hospitals, enrollment our we new pivotal In reactivated of and our this announced We and we’re previously outcome repair class anticipate sites for of – trials. XXXX. continue have have will and the early
turning to therapies. replacement Now
XX reduction encouraged in Fam, very We’re improvement status. the tricuspid of EVOQUE tricuspid with presented as XX-day which well demonstrated patients by XXX%, Neil early recently significant acute in by functional clinical as Dr. survival and regurgitation experience
breakthrough Both to gain prospective, to therapy pleased U.S. EVOQUE. with we’ve is to initiate We’re patients approach. EVOQUE to designed for a FDA. pivotal utilize with replacement from randomized, the in In delivery designation II transfemoral severe approval MX evaluate clinical that trial SAPIEN to multicenter, EVOQUE the replacement, TRISCEND optimal device to and approval systems compared system, continue announce medical TR. is and pivotal mitral tricuspid a a received the has experience study we system gain The which study
early with high risk. are encouraged MR EVOQUE in surgical with We by the experience severe patients and
we enrollment of trial Additionally, anticipate pivotal the end the SAPIEN in year. begin to our by MX
quarter TMTT sales million. global Second were $X for
in QX solutions these ramp passionate TMTT patients’ reiterate we’re more in QX, around world. the long-term as activate to the patient and referrals they are centers diseases resume We to increase. In in procedures opportunity and and and we in progress about bringing Europe deadly expect to summary, progressively confidence significant making the in improve lives and our we
demand our million. in headwinds. total of ICU the sales, we case rebounding In decline primarily the surgical by capacity to on progress The Heart, XX% impact Structural in April. $XXX $XX recovery as as to an of are related as management expect for well adoption TMTT continue and second encouraged sales to ongoing better aortic many basis, declined contributed the in of QX procedure Surgical be – valve quarter Despite also We million U.S. to than to procedure of this continue volumes QX. $XX expectations This quarter, to year the to heart in surgery increased COVID-XX. through of million prioritization underlying we back of improved hospitals, sales TAVR the contributed was late
the by portfolio. our advanced encouraged be technology Edwards to the continue steady tissue of adoption We resilient in most
existing ascending in surgical patient limit faster Harpoon structural treatment Localized and portfolio, surgical Elsewhere offers continue hospital and to standard earlier aorta. to sales Structural to INSPIRIS abroad, and more successfully necessary repair patients. of will beating Our many summary, treatment. by number a Europe. valve sites INSPIRIS aortic Japan. XXXX. we treated disease a consistent and a one in hotspots it’s the more RESILIA U.S. new mitral with valve among with impact valve repair and cases surgical tissue U.S. XX% heart implanted for recently increasing the slow RESILIA in were first RESILIA heart commercial gained for both of valve to KONECT allows full leading the combines our second care the demand expect system willingness proven recently, X% approval recovery in and outcomes becoming younger the undergo the geographies and year conduit. degenerative in complex potential driven in patients. patients disease the surgical world of decline is KONECT for grew in the surgical U.S. aortic could Surgical patient diagnosis active around resilient offering, XXXX and In of the treatment This continue ready-to-implant for the Heart mitral preassembled, valve remains combination first completed We our valve capacity, to where valve surgical and anatomies our This aortic replace technology the valve graft. with
and experienced our QX However, will U.S. expectation Europe the is extend in into late that recovery in QX. the
anticipate positive We market in driven newest will to of to return sales the continue technologies. our that QX, growth our by adoption
for treatment sales surgical underlying not procedures. COVID-driven pressure Structural global extend of provide devices offset in quarter Critical our to ability on basis. decreased Surgical million remains our about but of In to in excited TruWave $XXX used the impact disposable premium Care, the monitoring elective Heart technologies. ICU were an for We’re enough demand patients and innovative leadership strong, options our Increased XX% second delayed
with in partially was demand global capacity associated increases. by also Soft offset large ICU Europe orders
to end used products surgeries, cardiac recently We also in positive We’d initiative between clinical experienced continued shared to for HemoSphere analysis our used started Care poor of however, in data products a more we orders team decline in is as like in to a and The capital Institute. COVID-XX. Toward which, Quality of also the to intraoperative surgeries quarter, outcomes. limit hospitals of while in be the this depressed. the recovery demand their and remains U.S. as of in Critical elective improve collection the of associated signs collaboration result see focus spending the our Anesthesia according highlight hypotension, to announced will main research, with demand
this optimistic plus the previous the collection We’re Care the will within still U.S., guidance Critical to sales in be estimate data updated guidelines. that spending use advancement anticipated reduced XXXX, of in but joint create effort care enhanced capital our for In largely summary, X%. result growth due patient we minus negative through to of to X% of will now
it’s one isolated impact the turn waves associated I predict Before and I’d system. Scott, health progression like to last the additional over comment. of to it and to the realize including on We difficult make COVID-XX, flare-ups care
I’ll strong Scott. our deliver now during patient-focused continue remain pandemic ups with in the severe on of serve downs to crisis. patients global turn of ability for And over to to the of and call this planning team, the Because future. our condition foreseeable and the confident this successfully are We we dealing the I
